Meet the Elite Rated investment millennials
Millennials have gained a reputation for job-hopping, with a “job for life” becoming a thing of the...
AXA Framlington American Growth
Innovation, unique brands and intellectual property are the sort of features that can give companies a competitive advantage, helping them grow into market leaders. These kinds of stories are what manager Steve Kelly and his team hope to uncover for this fund in their quest for growth stocks in the US market.
Our opinion
Steve is an extremely experienced manager, backed up by a well-resourced team. The focus on strong growth allows the AXA Framlington American Growth fund to be able to benefit from exciting, less researched companies in the US market. The growth bias naturally leans towards this fund performing better when these stocks are in favour.
Company description
AXA Investment Management (AXA IM) is the asset management arm of the eponymous French insurance giant. Framlington Investment Managers was acquired by AXA and Framlington Equities provides a dynamic, autonomous investment culture combined with the stability and operational scale that comes with being part of one of the world’s largest investment managers. AXA IM was awarded the Elite Provider for Equities rating in 2015, 2016 and 2018.
Fund manager
Steve Kelly's experience in US equity markets spans more than 25 years and he has run this fund since he joined AXA in 1997. Steve started his career at Olliff & Partners as a trainee in the equity research department, before joining the US desk at Capel Cure Myers as an assistant fund manager, where he was later promoted to fund manager. He graduated from the University of Exeter with an honours degree in Economics.
You need to be able to innovate and change behaviour as a result of innovation, and that leads to certain sector biases that emerge. It’s no good innovating in the consumer staples sector; nobody’s ever going to change the way people wash their hair.
Steve KellyFund manager
Investment process
As the name suggests, AXA Framlington American Growth has a strong growth bias and Steve aims to invest in companies exhibiting genuine organic growth. Finding the stories that fit his stock-picking framework is what Steve believes will provide investors with superior returns over the long term. Meetings with management are central to the research process; the team collectively conduct more than 200 company meetings per year. Steve benefits from the cross-fertilisation of investment ideas provided by Framlington managers, notably in technology, healthcare and biotechnology. Around a third of the portfolio is typically invested in tech stocks. The fund tends to have a considerable weighting in mid-cap stocks. The US equity team support a collaborative environment whereby stock ideas are openly shared between the fund managers.
Risk
The nature of growth companies, which tend to be cyclical, means the fund will be more volatile than the typical large-cap focused US fund. Investors should be aware of the fund’s heavy style bias and the fund may struggle during periods when the value style of investing is in favour.
See more
Read more about this fund
The information, data, analyses, and opinions contained herein (1) include the proprietary information of FundCalibre, (2) may not be copied or redistributed without prior permission, (3) do not constitute investment advice offered by FundCalibre, (4) are provided solely for informational purposes and therefore are not an offer to buy or sell a fund, and (5) are not warranted to be correct, complete, or accurate. FundCalibre shall not be responsible for any trading decisions, damages, or other losses resulting from, or related to, this information, data, analyses, or opinions or their use. The Elite Fund rating is subjective in nature and reflects FundCalibre’s current expectations of future events/behaviour as they relate to a particular fund. Because such events/behaviour may turn out to be different than expected, FundCalibre does not guarantee that a fund will perform in line with its FundCalibre benchmark. Likewise, the Elite Fund rating should not be seen as any sort of guarantee or assessment of the creditworthiness of a fund nor of its underlying securities and should not be used as the sole basis for making any investment decision. FundCalibre disclaims any responsibility for trading decisions, damages or other losses resulting from any use of the Elite Fund rating. All performance data, as well as fund size, OCF, AMC, annual income (historic), share price discount or premium, is sourced directly from FE Analytics, and will change periodically.